Hepatoblastoma — Trials

Hepatoblastoma — Trials · CancerIndex

Clinical trials

Registered studies

61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 11
Ph III recruiting: 1
Growth YoY: —
Industry share: 12%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05322187	Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc)	unknown	Phase 2 / Phase 3	15	RenJi HospitalOTHER	1	Apr 11, 2022	clinicaltrials
NCT03728543	the Efficacy and Safety of Sugammadex in Children 0-2 Years Old	unknown	Phase 2 / Phase 3	62	Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER	1	Nov 2, 2018